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ABSTRACT
A  simple,  sensitive  and  reproducible  UV  visible  spectrophotometric  method  has  been  developed  for  the  quantitative 
determination of fenofibrate in bulk drug and pharmaceutical dosage forms using MBTH reagent. The method is based on 
the measurement of absorbance of fenofibrate in methanol (0.5% MBTH in 0.5% HCl and 1% FeCl3 in 0.5% HCl) at 596 
nm. Beer’s law is obeyed over the linear range 2-5µg /ml of fenofibrate for the method with apparent molar absorptivity 
value of 1909.5905 L mol
-1cm
-1. The method was validated in accordance with the current ICH guidelines. The precision 
results, expressed by reproducibility (RSD  1.7%) and repeatability (RSD  1.5%), were satisfactory. The accuracy is also 
satisfactory (RSD  0.200532%). The result demonstrated that the proposed method is accurate, precise and reproducible.
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INTRODUCTION
Fenofibrate  which  is  chemically  propan-2-yl  2-{4-[(4-
chlorophenyl)  carbonyl]  phenoxy}-methyl  propanoate. 
[1] It  
is  mainly  used  to  reduce  cholesterol  levels  in  patients  at  
risk  of  cardiovascular   disease.  Like    other  fibrates,  it  
reduces  both  low-density  lipoprotein (LDL)  and  very  low  
density  lipoprotein  (VLDL) levels,  as well as increasing 
high  density  lipoprotein  (HDL)  levels  and  reducing 
triglycerides levels.  It also  appears  to  have  a  beneficial  
effect  on  the  insulin  resistance  featured  by  the metabolic  
syndrome. 
[2-4]
(Chemical structure of fenofibrate)
High  performance  liquid  chromatography (HPLC) 
[5]  and  
thin  layer chromatography  methods 
[6]  were  reported  for  
the  estimation  of  fenofibrate  in biological  fluid  such  as  
plasma,  serum  and  urine  but  chromatographic  techniques  
are  time  consuming,  costly  and  time  expensive. A  survey  
of  literature  has  not revealed  any  simple  UV-Visible  
spectrophotometric  method  for  the  specific determination  
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of  fenofibrate  in  bulk  drugs,  formulation  and  dissolution  
media  of oral  formulations.  The  objective  of  the  present  
study    was    to    develop    simple,    precise    and    accurate  
analytical  method  with  the  better  detection  range  for 
estimation    of    fenofibrate    UV-Visible    range    by    the  
addition    of    MBTH    reagent    in    bulk,    pharmaceutical  
formulation  and  in  vitro  studies  of  oral  formulations.  
The    developed    method    was    validated    as    per    ICH  
guidelines  and  USP  requirement.
[7-8]
MATERIALS AND METHODS
A  SHIMADZU  model  PHARMASPEC-1800 UV-Vis 
spectrophotometer with 1.0 cm matched cells was used for 
the  electronic  spectral  measurements.  Fenofibrate  and  all 
other  chemicals  used  were  analytical  reagent  grade  (AR 
grade).  Methanol  is  used  as  solvent  in  all  experimental 
purpose. Fenofibrate pure drug (certified to be 99.76%) was 
kindly provided by  Lupin  pharmaceuticals ltd.,  India. as a 
gift  sample.  FINATE-160  (160  mg  fenofibrate)  were 
manufactured  by  FRANCO  INDIAN  Remedies  Pvt. Ltd., 
India and purchased.                           
Solutions
An accurately weighed quantity of 10 mg Fenofibrate  was 
transferred in to 100 ml volumetric flask with methanol and 
sonicated.  The  volume  was  made  up  to  the  mark  with 
methanol. Aliquots of this standard stock solution (SSS) were 
transferred  to  10  ml  volumetric  flask  (in  different 
concentrations) and to this 2.5ml of 0.5% MBTH and 2.5ml 
of 1% ferric chloride (both in 0.5% HCl) were added. Then Kutty et al. / Validated UV-Visible Spectrophotometric Method for the Estimation of Fenofibrate…..……
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the solutions are made up to the mark with methanol and kept 
for 20 minutes to form a blue-green complex and scanned 
over visible range of 400-800 nm. An overlay spectrum of 
drug was drawn out and selected the wavelength 596 nm for 
the  analysis  at  which  drug  showed  maximum  absorbance 
(Fig. 1).
Procedure
For calibration curve; (study of Beer’s- Lambert’s law) 
From SSS 0.2 ml-0.5ml were pipetted out and transferred to 
10 ml standard flask  and then  2.5  ml of 0.5 %  MBTH in 
0.5% HCl, 2.5 ml 1% FeCl3 in 0.5% HCl were added to each 
flask and then the volume is made up with methanol and kept 
as such for 20 minutes  to form a  blue-green complex  and 
scanned at 596 nm (Fig. 2 and Table 1). Absorbance plotted 
against concentration and calibration graph were recorded.
For absorptivity study
From  the  SSS,  a  solution  of  2μg/ml  concentration  was 
prepared.  Absorbance  of  such  five  of  fenofibrate  standard 
solution measured and results of absorptivity study drawn out 
by A1% 1cm (Table 2).
Estimation  of  fenofibrate  in  tablet  formulation  sample
Ten tablets were weighed accurately and powdered. Powder 
equivalent to 10 mg  (label claim -160 mg) was taken and 
transferred  to  100  ml  volumetric  flask  and  dissolved  in 
methanol,  sonicated  for  10  minutes,  filtered  and  further 
diluted  to  get  final  concentration  100µg/ml  of  fenofibrate 
(label  claim  basis).  From  the  above  solution  0.2  ml-0.5ml 
were pipetted out and transferred to 10 ml standard flask and 
then 2.5 ml of 0.5 % MBTH in 0.5% HCl, 2.5 ml 1% FeCl3 in 
0.5% HCl were added to each flask and then the volume is 
made up with methanol and kept as such for 20 minutes to 
form a blue-green complex and scanned at 596 nm (Table 3).
Table 1: Caliberation Curve
S. No Concentration (µg/ml) Absorbance
1. 2 0.208
2. 3 0.310
3. 4 0.419
4. 5 0.502
Table 2: Absorptivity (1%, 1cm) values of Fenofibrate at 596 nm 
S. No Conc. (g/100ml) Abs. A(1%, 1cm)
1. 0.0002002 0.382 1908.0919
2. 0.0002005 0.386 1905.1870
3. 0.0002003 0.378 1906.1692
4. 0.0002009 0.389 1907.2867
5. 0.0002004 0.379 1909.2175
Mean 1907.19046
±SD 1.53876
%RSD 0.080682
Table 3: Estimation of Fenofibrate in tablet formulation
S.
No.
Wt. Of tablet
powder taken mg(label 
claim 160mg)
Abs. at
596 nm
Amount of 
drug per 
tablet (mg)
% 
Purity
1. 0.045 0.382 0.1598 99.91
2. 0.0451 0.385 0.1607 100.47
3. 0.0442 0.380 0.1618 101.18
4. 0.0446 0.384 0.1621 101.33
5. 0.044 0.381 0.1630 101.91
Mean 100.96
± SD 0.7794
% RSD 0.7719
RESULT AND DISCUSSION
The method  was accurate, simple, rapid, reliable,  sensitive 
and reproducible. The wavelength 596nm was selected which 
showed good linearity between the concentrations.
Validation of analytical data
The  method  was  validated  in  accordance  with  the  current 
ICH  guidelines.  The  study  of  Beer’s- Lambert’s  law  was 
checked  by  preparing  standard  solution  at  four  different 
concentration and the linearity of the calibration graphs and 
conformity  of  the  UV-VIS  measurement  of  the  proposed 
methods  to  Beer’s  law  were  proven  by  the  values  of  the 
correlation coefficient of the absorptivity study.  The linear 
range  of  concentration  for  the  analysis  of  fenofibrate was 
found  to  be  2-5µg/ml  for  UV-VIS  spectrophotometric 
method.
The  utility  of  this  method  was  verified  by  analysis  of 
recovery  of  the  assay  in  the  marketed  tablet  sample.  The 
tablet sample (label claim- 160mg) fenofibrate was prepared 
and processed according to the proposed method. 
Recoveries  were  determined  by  standard  addition  method 
(SAM). The mean % recoveries of fenofibrate by UV-VIS 
method were found to be 99.36% (Table 4).
[9]
The  reproducibility  and  repeatability  of  the  developed 
method were established by study of precision for fenofibrate 
determined by 5 replicate analyses on the tablet formulation. 
[10] The % RSD was found to be 1.7% and 1.5% respectively 
for UV-VIS spectroscopic methods (Table 5, 6 & 7).
Correlation coefficient for UV -VIS Spectrophotometric
Table 4: Determination of accuracy by percentage recovery method
Drug Level of 
addition
Amount of 
pure drug 
added 
(μg/ml)
Amount of 
pure drug 
recovered (mg)
% 
recovery
Fenofibrate
50% 0.005 0.01497 99.48
75% 0.007 0.01743 99.13
100% 0.010 0.01995 99.47
Mean 99.36
±SD 0.199249
%RSD 0.200532
Table 5: Reproducibility
S. No Conc. (μg/ml) Abs. at 596 nm
1. 2 0.211
2. 2 0.202
3. 2 0.204
4. 2 0.207
5. 2 0.203
Mean 0.2054
±SD 0.0036469
%RSD 1.7
Table 6: Repeatability
S. No Conc.(μg/ml) Abs. at 596 nm
1. 2 0.203
2. 2 0.202
3. 2 0.201
4. 2 0.208
5. 2 0.200
Mean 0.2028
±SD 0.0031144
%RSD 1.5
Table 7: Validation Parameters
S. No Parameter Result
1. Absorption  maxima (nm) 596
2. Linearity  range (µg /ml) 2-5
3. Slope 0.101
4. Intercept 0.003
5. Correlation  coefficient (r2) 0.998
6. Molar  absorptivity 1907.19046
7. Accuracy (% recovery) 99.36
8. Precision
a)Reproducibility %RSD 1.7
b)Repeatability %RSD 1.5Kutty et al. / Validated UV-Visible Spectrophotometric Method for the Estimation of Fenofibrate…..……
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Fig. 1: Overlay spectra of Fenbofibrate
Fig. 2: Plot of Beer’s Lambert’s law for Fenofibrate at 596 nm
method was found to be 0.998 of fenofibrate was found to be 
linear.
Ruggedness of the proposed  method  was carried out for 3 
different analysts. The result did not show any considerable 
statistical  difference  suggesting that  the  method  developed 
was rugged.
The stability study was carried out and dug was found to be 
stable between 20 to 35 minutes.
Validation  parameters  complies  the  applied 
spectrophotometric methods of analysis and were found to be 
simple,  sensitive,  accurate  and  satisfactory  capable  for 
determination  of  fenofibrate  in  tablet  formulation  with 
reproducible specific results. The linear concentration range 
of preordain elaborated method were observed wider. Thus, 
proposed  UV-VIS spectrophotometric  method is applicable 
for  the  quality  control  and  routine  analysis  and  may  also 
proposed for determination from biological fluid  other solid 
dosage form containing same drugs.
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